Site-Specific linkers offer precise coupling of cytotoxins or chemotherapeutic drugs to specific sites within antibody molecules. They ensure ADCs exhibit high homogeneity and an increased therapeutic index (TI). Beyond traditional cytotoxin-conjugated ADCs, site-specific linkers facilitate the development of various immunoconjugates, promising enhanced efficacy and safety across a broad spectrum of challenging diseases.